Covered recipient · General Payments record
BRUCE RANKIN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$1,612.22
12 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $1,013.69 | 4 |
| Food and Beverage | $598.53 | 8 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ModernaTX, Inc. | $1,394.72 | 10 |
| Amgen Inc. | $120.83 | 1 |
| Lilly USA, LLC | $96.67 | 1 |
Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRUCE RANKIN
NPI 1922027853 · CMS profile ID 132925
Allopathic & Osteopathic Physicians / Family Medicine
DELAND, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1922027853?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
12 matching records · $1,612.22 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–12 of 12.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ModernaTX, Inc. | $75.03 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558244 | CMS |
| ModernaTX, Inc. | $451.96 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558246 | CMS |
| ModernaTX, Inc. | $240.00 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558248 | CMS |
| ModernaTX, Inc. | $56.20 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558250 | CMS |
| ModernaTX, Inc. | $265.53 | 09/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558252 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558254 | CMS |
| ModernaTX, Inc. | $81.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558256 | CMS |
| ModernaTX, Inc. | $30.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558258 | CMS |
| ModernaTX, Inc. | $45.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558260 | CMS |
| ModernaTX, Inc. | $120.00 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152558262 | CMS |
| Amgen Inc. | $120.83 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111684396 | CMS |
| Lilly USA, LLC | $96.67 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136080574 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,755.45 | 1 |
| PY2025 | Principal investigator | $4,230,288.19 | 209 |
| PY2024 | Recipient | $1,330.16 | 13 |
| PY2024 | Principal investigator | $3,187,354.20 | 327 |
| PY2023 | Recipient | $893.27 | 4 |
| PY2023 | Principal investigator | $6,323,793.75 | 2,767 |
| PY2022 | Recipient | $462.00 | 2 |
| PY2022 | Principal investigator | $6,941,300.42 | 589 |
| PY2021 | Recipient | $15.00 | 1 |
| PY2021 | Principal investigator | $10,036,876.19 | 348 |
| PY2020 | Recipient | $10,602.17 | 4 |
| PY2020 | Principal investigator | $3,545,507.10 | 644 |
| PY2019 | Principal investigator | $2,410,610.06 | 875 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
349 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $15,213.07 | 12/31/2021 | Non-covered Recipient Entity ACCEL RESEARCH SITES DELAND CLINICAL RESEARCH UNIT | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 848739029 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 12/29/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in | No dispute reported | 06/30/2026 | 787819167 |
| Principal investigator 1 | PFIZER INC. | $63,863.88 | 12/29/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832538155 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $22,656.00 | 12/28/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575823 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,602.00 | 12/28/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819333 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,369.00 | 12/28/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819559 |
| Principal investigator 1 | PFIZER INC. | $66,862.91 | 12/28/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832538165 |
| Principal investigator 1 | ModernaTX, Inc. | $1,514.00 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945079 |
| Principal investigator 1 | ModernaTX, Inc. | $1,816.80 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945085 |
| Principal investigator 1 | ModernaTX, Inc. | $3,028.00 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945091 |
| Principal investigator 1 | ModernaTX, Inc. | $3,028.00 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945093 |
| Principal investigator 1 | ModernaTX, Inc. | $4,844.80 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945099 |
| Principal investigator 1 | ModernaTX, Inc. | $7,267.20 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945103 |
| Principal investigator 1 | ModernaTX, Inc. | $8,301.40 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945109 |
| Principal investigator 1 | ModernaTX, Inc. | $20,059.63 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945137 |
| Principal investigator 1 | ModernaTX, Inc. | $30,089.45 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945147 |
| Principal investigator 1 | ModernaTX, Inc. | $31,927.50 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945149 |
| Principal investigator 1 | ModernaTX, Inc. | $33,161.88 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945153 |
| Principal investigator 1 | ModernaTX, Inc. | $33,189.75 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945155 |
| Principal investigator 1 | ModernaTX, Inc. | $59,231.25 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945167 |
| Principal investigator 1 | ModernaTX, Inc. | $62,293.05 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945169 |
| Principal investigator 1 | ModernaTX, Inc. | $217,911.86 | 12/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945187 |
| Principal investigator 1 | PFIZER INC. | $722,086.16 | 12/24/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832537751 |
| Principal investigator 1 | PFIZER INC. | $951.60 | 12/23/2021 | Non-covered Recipient Entity University Clinical ResearchDeLand LLC | A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE | No dispute reported | 06/30/2026 | 832538175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,900.00 | 12/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819607 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,600.00 | 12/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819625 |
| Principal investigator 1 | ModernaTX, Inc. | $700.00 | 12/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945063 |
| Principal investigator 1 | ModernaTX, Inc. | $875.95 | 12/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945071 |
| Principal investigator 1 | ModernaTX, Inc. | $2,785.59 | 12/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945089 |
| Principal investigator 1 | ModernaTX, Inc. | $8,023.85 | 12/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945107 |
| Principal investigator 1 | ModernaTX, Inc. | $14,107.50 | 12/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945127 |
| Principal investigator 1 | ModernaTX, Inc. | $29,149.94 | 12/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945145 |
| Principal investigator 1 | Janssen Research & Development, LLC | $50.00 | 12/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819383 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 12/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819401 |
| Principal investigator 1 | Janssen Research & Development, LLC | $900.00 | 12/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,400.00 | 12/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819575 |
| Principal investigator 1 | ModernaTX, Inc. | $34,303.50 | 12/17/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945157 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,998.46 | 12/16/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851031567 |
| Principal investigator 1 | ModernaTX, Inc. | $1,514.00 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945075 |
| Principal investigator 1 | ModernaTX, Inc. | $1,514.00 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945077 |
| Principal investigator 1 | ModernaTX, Inc. | $3,330.80 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945095 |
| Principal investigator 1 | ModernaTX, Inc. | $4,844.80 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945097 |
| Principal investigator 1 | ModernaTX, Inc. | $8,478.40 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945111 |
| Principal investigator 1 | ModernaTX, Inc. | $13,323.19 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945121 |
| Principal investigator 1 | ModernaTX, Inc. | $18,053.67 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945131 |
| Principal investigator 1 | ModernaTX, Inc. | $36,371.09 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945159 |
| Principal investigator 1 | ModernaTX, Inc. | $48,138.21 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945161 |
| Principal investigator 1 | ModernaTX, Inc. | $82,058.75 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945175 |
| Principal investigator 1 | ModernaTX, Inc. | $93,565.15 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945177 |
| Principal investigator 1 | ModernaTX, Inc. | $101,740.74 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945179 |
| Principal investigator 1 | ModernaTX, Inc. | $192,552.84 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945185 |
| Principal investigator 1 | ModernaTX, Inc. | $724,152.64 | 12/15/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945189 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $202.50 | 12/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851031171 |
| Principal investigator 1 | GRT US Holding, Inc. | $6,450.00 | 12/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AV001 | No dispute reported | 06/30/2026 | 839391349 |
| Principal investigator 1 | GRT US Holding, Inc. | $1,500.00 | 12/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | AV001 | No dispute reported | 06/30/2026 | 839391351 |
| Principal investigator 1 | PFIZER INC. | $695.93 | 12/07/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832536425 |
| Principal investigator 1 | Astellas Pharma Inc | $1,428.79 | 12/02/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552937 |
| Principal investigator 1 | Astellas Pharma Inc | $144.84 | 12/02/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552943 |
| Principal investigator 1 | Astellas Pharma Inc | $2,996.31 | 12/02/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552949 |
| Principal investigator 1 | Astellas Pharma Inc | $296.39 | 12/02/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552955 |
| Principal investigator 1 | Eli Lilly and Company | $195.16 | 11/30/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 819468549 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $51,507.00 | 11/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575835 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,228.00 | 11/19/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819591 |
| Principal investigator 1 | ModernaTX, Inc. | $875.95 | 11/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945069 |
| Principal investigator 1 | ModernaTX, Inc. | $13,545.77 | 11/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945123 |
| Principal investigator 1 | ModernaTX, Inc. | $56,201.72 | 11/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945165 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $476.40 | 11/18/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851030051 |
| Principal investigator 1 | PFIZER INC. | $2,531.93 | 11/18/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832713223 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,300.00 | 11/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819312 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/17/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945061 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $3,614.00 | 11/12/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679507 |
| Principal investigator 1 | ABBVIE INC. | $150.00 | 11/10/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease | No dispute reported | 06/30/2026 | 792482527 |
| Principal investigator 1 | ModernaTX, Inc. | $13,930.52 | 11/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945125 |
| Principal investigator 1 | ModernaTX, Inc. | $63,058.50 | 11/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945171 |
| Principal investigator 1 | PFIZER INC. | $2,540.04 | 11/10/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832744479 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $2,710.50 | 11/05/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679505 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $50.00 | 11/03/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575813 |
| Principal investigator 1 | ModernaTX, Inc. | $141.08 | 11/03/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945057 |
| Principal investigator 1 | PFIZER INC. | $75.00 | 11/03/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832830839 |
| Principal investigator 1 | PFIZER INC. | $8,891.80 | 10/30/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832877883 |
| Principal investigator 1 | ModernaTX, Inc. | $705.38 | 10/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945065 |
| Principal investigator 1 | ModernaTX, Inc. | $2,116.13 | 10/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945087 |
| Principal investigator 1 | ModernaTX, Inc. | $12,404.34 | 10/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945119 |
| Principal investigator 1 | ModernaTX, Inc. | $167,105.90 | 10/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945183 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,640.53 | 10/28/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851029429 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 10/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945059 |
| Principal investigator 1 | ModernaTX, Inc. | $72,765.00 | 10/27/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945173 |
| Principal investigator 1 | PFIZER INC. | $11,379.86 | 10/27/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832721739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,778.00 | 10/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819659 |
| Principal investigator 1 | PFIZER INC. | $73.75 | 10/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832630179 |
| Principal investigator 1 | PFIZER INC. | $486.25 | 10/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832632445 |
| Principal investigator 1 | PFIZER INC. | $15.00 | 10/21/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832906061 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $60,738.00 | 10/20/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575845 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,608.00 | 10/20/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819351 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $1,500.00 | 10/19/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | C3718-301 | No dispute reported | 06/30/2026 | 831594747 |
| Principal investigator 1 | PFIZER INC. | $16,443.72 | 10/16/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832803589 |
| Principal investigator 1 | ModernaTX, Inc. | $1,633.50 | 10/13/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945081 |
| Principal investigator 1 | ModernaTX, Inc. | $142,446.60 | 10/13/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945181 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $1,175.00 | 10/13/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679501 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $770.00 | 10/13/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679503 |
| Principal investigator 1 | PFIZER INC. | $20,981.14 | 10/09/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832891913 |
| Principal investigator 1 | PFIZER INC. | $1,537.50 | 10/08/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832882115 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,302.85 | 10/07/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827899257 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,302.85 | 10/07/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827899259 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 10/06/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819641 |
| Principal investigator 1 | PFIZER INC. | $43,850.26 | 10/05/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832797475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $150.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819294 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819369 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819421 |
| Principal investigator 1 | Janssen Research & Development, LLC | $330.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819437 |
| Principal investigator 1 | Janssen Research & Development, LLC | $435.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819453 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819491 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,312.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819507 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,328.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819521 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,768.00 | 10/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819541 |
| Principal investigator 1 | ModernaTX, Inc. | $846.45 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945067 |
| Principal investigator 1 | ModernaTX, Inc. | $1,141.43 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945073 |
| Principal investigator 1 | ModernaTX, Inc. | $1,751.90 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945083 |
| Principal investigator 1 | ModernaTX, Inc. | $7,053.75 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945101 |
| Principal investigator 1 | ModernaTX, Inc. | $7,476.98 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945105 |
| Principal investigator 1 | ModernaTX, Inc. | $10,722.98 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945113 |
| Principal investigator 1 | ModernaTX, Inc. | $11,997.79 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945115 |
| Principal investigator 1 | ModernaTX, Inc. | $12,217.10 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945117 |
| Principal investigator 1 | ModernaTX, Inc. | $16,469.87 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945129 |
| Principal investigator 1 | ModernaTX, Inc. | $18,832.23 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945133 |
| Principal investigator 1 | ModernaTX, Inc. | $18,832.23 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945135 |
| Principal investigator 1 | ModernaTX, Inc. | $20,599.52 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945139 |
| Principal investigator 1 | ModernaTX, Inc. | $23,102.96 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945141 |
| Principal investigator 1 | ModernaTX, Inc. | $24,690.69 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945143 |
| Principal investigator 1 | ModernaTX, Inc. | $32,993.60 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945151 |
| Principal investigator 1 | ModernaTX, Inc. | $52,697.93 | 10/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH D | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 860945163 |
| Principal investigator 1 | PFIZER INC. | $90.00 | 09/30/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832837299 |
| Principal investigator 1 | Moderna TX, Inc. | $141.08 | 09/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342967 |
| Principal investigator 1 | Moderna TX, Inc. | $542.70 | 09/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342983 |
| Principal investigator 1 | PFIZER INC. | $8,916.94 | 09/29/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832908283 |
| Principal investigator 1 | PFIZER INC. | $41,737.49 | 09/25/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832694825 |
| Recipient | Eli Lilly and Company | $15.00 | 09/24/2021 | Covered Recipient Physician | A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 819443119 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,283.20 | 09/24/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,784.00 | 09/24/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819061 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 09/24/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819257 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $3,422.31 | 09/23/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827899103 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $3,422.31 | 09/23/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827899117 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $40,084.00 | 09/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,736.00 | 09/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819079 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,822.00 | 09/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819235 |
| Principal investigator 1 | PFIZER INC. | $464.00 | 09/22/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832744469 |
| Principal investigator 1 | PFIZER INC. | $9,945.00 | 09/22/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832902909 |
| Principal investigator 1 | PFIZER INC. | $20,463.36 | 09/21/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832848203 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $5,995.00 | 09/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575793 |
| Principal investigator 1 | PFIZER INC. | $21,839.00 | 09/14/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832835035 |
| Principal investigator 1 | Moderna TX, Inc. | $6,021.34 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342915 |
| Principal investigator 1 | Moderna TX, Inc. | $5,600.00 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342919 |
| Principal investigator 1 | Moderna TX, Inc. | $350.00 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342953 |
| Principal investigator 1 | Moderna TX, Inc. | $500.00 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342997 |
| Principal investigator 1 | Moderna TX, Inc. | $1,551.83 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343013 |
| Principal investigator 1 | Moderna TX, Inc. | $1,269.68 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343041 |
| Principal investigator 1 | Moderna TX, Inc. | $28,215.00 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343103 |
| Principal investigator 1 | Moderna TX, Inc. | $68,453.10 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343133 |
| Principal investigator 1 | Moderna TX, Inc. | $515.57 | 09/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343159 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 09/09/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832830691 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $7,000.00 | 09/08/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575781 |
| Principal investigator 1 | PFIZER INC. | $33,407.89 | 09/08/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832732819 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $75.00 | 09/07/2021 | Non-covered Recipient Entity Accel Research Sites - DeLand Clinical Research Unit | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 828418705 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $55.00 | 09/07/2021 | Non-covered Recipient Entity Accel Research Sites - DeLand Clinical Research Unit | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 828418707 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $35.00 | 09/07/2021 | Non-covered Recipient Entity Accel Research Sites - DeLand Clinical Research Unit | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 828418709 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $17.00 | 09/07/2021 | Non-covered Recipient Entity Accel Research Sites - DeLand Clinical Research Unit | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 828418711 |
| Principal investigator 1 | PFIZER INC. | $2,025.00 | 09/04/2021 | Non-covered Recipient Entity University Clinical ResearchDeLand LLC | A 16WEEK PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE | No dispute reported | 06/30/2026 | 832900807 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,287.00 | 09/03/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819221 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $11,379.00 | 09/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 787575771 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,281.00 | 09/01/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819093 |
| Principal investigator 1 | Moderna TX, Inc. | $36,605.25 | 09/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342937 |
| Principal investigator 1 | PFIZER INC. | $33,369.45 | 08/31/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832806151 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,517.00 | 08/25/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819113 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,741.00 | 08/25/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819201 |
| Principal investigator 1 | Moderna TX, Inc. | $67,541.85 | 08/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343109 |
| Principal investigator 1 | Moderna TX, Inc. | $37,199.25 | 08/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343153 |
| Principal investigator 1 | PFIZER INC. | $18,439.49 | 08/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832732345 |
| Principal investigator 1 | PFIZER INC. | $40,567.65 | 08/24/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832757446 |
| Principal investigator 1 | Eli Lilly and Company | $1,500.00 | 08/23/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | No dispute reported | 06/30/2026 | 819469025 |
| Principal investigator 1 | Astellas Pharma Inc | $1,000.00 | 08/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552429 |
| Principal investigator 1 | Astellas Pharma Inc | $1,500.00 | 08/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552435 |
| Principal investigator 1 | Astellas Pharma Inc | $7,500.00 | 08/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 1 Open-label Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Renal Function | No dispute reported | 06/30/2026 | 813552447 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $955.62 | 08/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851026865 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $3,307.49 | 08/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851026867 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $2,274.84 | 08/19/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827898499 |
| Principal investigator 1 | PFIZER INC. | $12,723.83 | 08/14/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832726475 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $4,390.00 | 08/12/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827898491 |
| Principal investigator 1 | Janssen Research & Development, LLC | $75,493.00 | 08/09/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819131 |
| Principal investigator 1 | PFIZER INC. | $12,480.85 | 08/07/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832890157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 08/06/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819183 |
| Principal investigator 1 | PFIZER INC. | $30.00 | 08/05/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832785873 |
| Principal investigator 1 | PFIZER INC. | $3,888.03 | 08/03/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832722819 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 07/28/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease | No dispute reported | 06/30/2026 | 792468883 |
| Principal investigator 1 | PFIZER INC. | $4,775.66 | 07/24/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832889343 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,521.00 | 07/23/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819148 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,174.00 | 07/23/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787819274 |
| Principal investigator 1 | Moderna TX, Inc. | $35,788.50 | 07/23/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343171 |
| Principal investigator 1 | PFIZER INC. | $1,856.00 | 07/22/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 832750819 |
| Principal investigator 1 | Moderna TX, Inc. | $28,487.63 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342931 |
| Principal investigator 1 | Moderna TX, Inc. | $26,336.14 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342949 |
| Principal investigator 1 | Moderna TX, Inc. | $30,836.43 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342973 |
| Principal investigator 1 | Moderna TX, Inc. | $28,875.49 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342989 |
| Principal investigator 1 | Moderna TX, Inc. | $28,734.41 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343007 |
| Principal investigator 1 | Moderna TX, Inc. | $32,430.11 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343025 |
| Principal investigator 1 | Moderna TX, Inc. | $53,080.11 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343035 |
| Principal investigator 1 | Moderna TX, Inc. | $4,921.97 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343069 |
| Principal investigator 1 | Moderna TX, Inc. | $31,867.29 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343091 |
| Principal investigator 1 | Moderna TX, Inc. | $13,853.57 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343115 |
| Principal investigator 1 | Moderna TX, Inc. | $1,544.13 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343127 |
| Principal investigator 1 | Moderna TX, Inc. | $29,209.68 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343139 |
| Principal investigator 1 | Moderna TX, Inc. | $9,977.85 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343145 |
| Principal investigator 1 | Moderna TX, Inc. | $11,937.71 | 07/21/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343177 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 07/21/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC dba Accel Research Sites | A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 832729467 |
| Principal investigator 1 | PFIZER INC. | $4,296.41 | 07/17/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832775061 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $11,745.50 | 07/17/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679499 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $128,891.03 | 07/14/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254735 |
| Principal investigator 1 | PFIZER INC. | $1,296.01 | 07/13/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832815327 |
| Principal investigator 1 | Moderna TX, Inc. | $66,446.33 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342909 |
| Principal investigator 1 | Moderna TX, Inc. | $144,108.11 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342925 |
| Principal investigator 1 | Moderna TX, Inc. | $168,705.18 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342943 |
| Principal investigator 1 | Moderna TX, Inc. | $53,697.26 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342959 |
| Principal investigator 1 | Moderna TX, Inc. | $60,505.79 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342963 |
| Principal investigator 1 | Moderna TX, Inc. | $81,286.13 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342977 |
| Principal investigator 1 | Moderna TX, Inc. | $161,657.84 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806342993 |
| Principal investigator 1 | Moderna TX, Inc. | $55,769.51 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343003 |
| Principal investigator 1 | Moderna TX, Inc. | $38,387.25 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343019 |
| Principal investigator 1 | Moderna TX, Inc. | $149,860.13 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343030 |
| Principal investigator 1 | Moderna TX, Inc. | $67,300.47 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343047 |
| Principal investigator 1 | Moderna TX, Inc. | $47,449.94 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343081 |
| Principal investigator 1 | Moderna TX, Inc. | $164,236.95 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343099 |
| Principal investigator 1 | Moderna TX, Inc. | $71,113.95 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343121 |
| Principal investigator 1 | Moderna TX, Inc. | $36,784.67 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343149 |
| Principal investigator 1 | Moderna TX, Inc. | $15,077.07 | 07/09/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343189 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,183.12 | 07/08/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851025677 |
| Principal investigator 1 | PFIZER INC. | $1,244.03 | 07/03/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832841529 |
| Principal investigator 1 | PFIZER INC. | $1,991.94 | 06/26/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832904319 |
| Principal investigator 1 | Janssen Research & Development, LLC | $40,929.00 | 06/25/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819045 |
| Principal investigator 1 | Janssen Research & Development, LLC | $270.00 | 06/23/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818931 |
| Principal investigator 1 | PFIZER INC. | $2,086.44 | 06/22/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832795581 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 06/18/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819023 |
| Principal investigator 1 | Moderna TX, Inc. | $74,066.40 | 06/18/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 806343075 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 06/17/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease | No dispute reported | 06/30/2026 | 792463353 |
| Principal investigator 1 | PFIZER INC. | $1,391.86 | 06/12/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832771655 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $1,500.00 | 06/11/2021 | Non-covered Recipient Entity ACCEL CLINICAL | A PHASE 1 STUDY OF THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF RIPRETINIB IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | No dispute reported | 06/30/2026 | 827897265 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,220.73 | 06/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851032601 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $2,143.80 | 06/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851032603 |
| Principal investigator 1 | PFIZER INC. | $7,958.29 | 06/09/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832737943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 06/07/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818911 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,106.43 | 06/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254715 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,106.43 | 06/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254717 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,106.43 | 06/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254719 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,106.43 | 06/01/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254721 |
| Principal investigator 1 | PFIZER INC. | $7,932.69 | 05/29/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832740155 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $25.00 | 05/27/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679497 |
| Principal investigator 1 | Janssen Research & Development, LLC | $82,025.00 | 05/25/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787819007 |
| Principal investigator 1 | AstraZeneca UK Limited | $193.31 | 05/24/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH LLC | A single dose, non-randomized, open-label, parallel group study to assess the pharmacokinetics, safety and tolerability of AZD9977 in participants with renal impairment | No dispute reported | 06/30/2026 | 826474019 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,310.00 | 05/24/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818893 |
| Principal investigator 1 | PFIZER INC. | $15,188.97 | 05/22/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832796444 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $2,143.80 | 05/20/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851032523 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $25.00 | 05/20/2021 | Non-covered Recipient Entity University Clinical Res-Deland, LLC (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807679495 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,250.00 | 05/19/2021 | Non-covered Recipient Entity University Clinical Research Deland,LLC | MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 | No dispute reported | 06/30/2026 | 838371121 |
| Principal investigator 1 | PFIZER INC. | $19,404.30 | 05/15/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832763249 |
| Principal investigator 1 | PFIZER INC. | $13,058.51 | 05/14/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 832827145 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 05/12/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease | No dispute reported | 06/30/2026 | 792456851 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,202.43 | 05/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254681 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $402.43 | 05/10/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254683 |
| Principal investigator 1 | PFIZER INC. | $31,346.54 | 05/08/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832824539 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $1,102.43 | 05/07/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $100.00 | 05/07/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818877 |
| Principal investigator 1 | PFIZER INC. | $35,908.81 | 05/01/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832750829 |
| Principal investigator 1 | PFIZER INC. | $2,232.00 | 04/28/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832819261 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $500.00 | 04/27/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | C3718-301 | No dispute reported | 06/30/2026 | 831592379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $211,743.99 | 04/27/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818989 |
| Principal investigator 1 | PFIZER INC. | $28,082.78 | 04/24/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832896849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,120.00 | 04/23/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818857 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,350.00 | 04/23/2021 | Non-covered Recipient Entity University Clinical Research Deland,LLC | MEQ00066 Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal MenACYW Conjugate Vaccine in Older Adults Who Received a Primary Vaccination 3 or More Years Earlier in Study MET49 | No dispute reported | 06/30/2026 | 838371113 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $6,000.00 | 04/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851032457 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,250.00 | 04/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age | No dispute reported | 06/30/2026 | 851032459 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $6,000.00 | 04/21/2021 | Non-covered Recipient Entity University Clinical Research-Deland, LLC d/b/a Accel Research Sites | A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents | No dispute reported | 06/30/2026 | 823607815 |
| Principal investigator 1 | PFIZER INC. | $43,221.07 | 04/17/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832847841 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 04/16/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818967 |
| Principal investigator 1 | Horizon Therapeutics plc | $2,031.00 | 04/14/2021 | Non-covered Recipient Entity AVAIL RESEARCH | A MULTICENTER EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA (PEGLOTICASE) (MIRROR OL ) | No dispute reported | 06/30/2026 | 811912521 |
| Principal investigator 1 | PFIZER INC. | $55,969.02 | 04/10/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832780479 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 04/07/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818951 |
| Principal investigator 1 | PFIZER INC. | $153,367.55 | 04/03/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832897179 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 03/29/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects with Moderately to Severely Active Ulcerative Colitis or Crohns Disease | No dispute reported | 06/30/2026 | 792436029 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $5,657.36 | 03/29/2021 | Non-covered Recipient Entity University Clinical Research | Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis | No dispute reported | 06/30/2026 | 819903457 |
| Principal investigator 1 | PFIZER INC. | $132,483.77 | 03/27/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832835395 |
| Principal investigator 1 | Janssen Research & Development, LLC | $243,009.00 | 03/24/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45,980.00 | 03/24/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818841 |
| Principal investigator 1 | PFIZER INC. | $126,383.80 | 03/20/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832796245 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,714.01 | 03/17/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818746 |
| Principal investigator 1 | PFIZER INC. | $133,382.70 | 03/16/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832769227 |
| Principal investigator 1 | PFIZER INC. | $235,444.80 | 03/13/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832750563 |
| Principal investigator 1 | Horizon Therapeutics plc | $3,000.00 | 03/10/2021 | Non-covered Recipient Entity AVAIL RESEARCH | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF METHOTREXATE TO INCREASE RESPONSE RATES IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING KRYSTEXXA (PEGLOTICASE) (MIRROR RANDOMIZED CONTROLLED TRIAL RCT ) | No dispute reported | 06/30/2026 | 811912499 |
| Principal investigator 1 | PFIZER INC. | $702,170.80 | 03/06/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832785787 |
| Principal investigator 1 | PFIZER INC. | $16,733.27 | 02/27/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832809686 |
| Principal investigator 1 | PFIZER INC. | $1,547.31 | 02/24/2021 | Non-covered Recipient Entity AVAIL CLINICAL RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832796237 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $58.00 | 02/23/2021 | Non-covered Recipient Entity University Clinical Research | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | No dispute reported | 06/30/2026 | 819903463 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91,613.00 | 02/23/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818725 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 02/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254619 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 02/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254621 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 02/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254623 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 02/22/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254625 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,670.00 | 02/22/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818821 |
| Principal investigator 1 | PFIZER INC. | $2,777.64 | 02/20/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832713297 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,988.00 | 02/19/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818709 |
| Principal investigator 1 | PFIZER INC. | $4,773.64 | 02/13/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832693403 |
| Principal investigator 1 | PFIZER INC. | $1,240.66 | 02/06/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832743773 |
| Principal investigator 1 | PFIZER INC. | $2,724.80 | 02/05/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC dba Accel Research Sites | A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 832905215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 02/04/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818799 |
| Principal investigator 1 | PFIZER INC. | $6,036.57 | 01/30/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832723059 |
| Principal investigator 1 | SEIKAGAKU CORPORATION | $2,982.00 | 01/28/2021 | Non-covered Recipient Entity Accel Research Sites (WIRE) | 6603/1133 | No dispute reported | 06/30/2026 | 807677823 |
| Principal investigator 1 | Eli Lilly and Company | $4,629.26 | 01/26/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 819466891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $208,240.00 | 01/26/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults | No dispute reported | 06/30/2026 | 787818693 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,090.00 | 01/26/2021 | Non-covered Recipient Entity Univ Clnc Rsrch - Deland, Llc | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 787818781 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254441 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254443 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254445 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254447 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254449 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254451 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254453 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254455 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254457 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254459 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254461 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254463 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254465 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254467 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254469 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254471 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254473 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254475 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254477 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254479 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254481 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254483 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254485 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254487 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.36 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254489 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254491 |
| Principal investigator 1 | Emergent BioSolutions Inc. | $217.43 | 01/25/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH -DELAND LLC | EBS.AVA.210 | No dispute reported | 06/30/2026 | 785254493 |
| Principal investigator 1 | PFIZER INC. | $6,587.38 | 01/23/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832822939 |
| Principal investigator 1 | Eli Lilly and Company | $318,936.09 | 01/19/2021 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 819470033 |
| Principal investigator 1 | PFIZER INC. | $7,160.46 | 01/16/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832836565 |
| Principal investigator 1 | PFIZER INC. | $4,096.95 | 01/12/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC dba Accel Research Sites | A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 832799615 |
| Principal investigator 1 | PFIZER INC. | $6,540.13 | 01/08/2021 | Non-covered Recipient Entity University Clinical Research DeLand LLC | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 832711871 |
| Principal investigator 1 | PFIZER INC. | $156.60 | 01/05/2021 | Non-covered Recipient Entity Avail Clinical Research LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 832920599 |